Private
Avails Medical, a Menlo Park, California diagnostics company, has secured an award worth up to $2.5 million from CARB-X to develop an electronic antibiotic susceptibility testing (AST) device.
The innovation would expedite healthcare providers’ ability to determine the most effective... Read More »
The United States Departments of Defense (DoD) and Health and Human Services (HHS) awarded $231.8 million to Ellume USA LLC this week to expand the domestic production capacity of its COVID-19 Home Test.
These funds will increase Ellume’s U.S. production capacity by 640,000 tests per day by... Read More »
With fears growing over mutated strains of the SARS-CoV-2 virus that have spread from the United Kingdom, South Africa, and Brazil, Innova Medical Group, Inc. provided some relief this week with confirmation that its antigen test kits are capable of identifying all three.
"As these dangerous... Read More »
Novartis signed an agreement with Pfizer-BioNTech to leverage its manufacturing capacity and capabilities to support the production of the Pfizer-BioNTech COVID-19 Vaccine.
Through this agreement, Novartis will use its aseptic manufacturing facilities at its site in Stein, Switzerland. Through... Read More »
A new forecast from the Institute for Health Metrics and Evaluation at the University of Washington establishes the danger of two new variants of COVID-19, warning of the possibility of a surge of deaths later this year, even despite the vaccine rollout.
According to the report, B.1.351 -- the... Read More »
Those residents of the European Union 18 years or older will now be able to get AstraZeneca’s COVID-19 vaccine to prevent COVID-19, following a conditional marketing authorization granted by the European Medicines Agency (EMA).
The approval will allow AstraZeneca to begin working with the EU... Read More »
The Coalition for Epidemic Preparedness Innovation, or CEPI, is awarding up to $140 million in funding to research institutions for clinical data on COVID-19 vaccines.
This initiative aims to fill in existing clinical research and development gaps to expand access to COVID-19 vaccines. The... Read More »
The U.S. Department of Homeland Security Cybersecurity and Infrastructure Security Agency (CISA) recently joined Cactus League officials and affiliates in an exercise designed to review pre-incident preparedness measures and response plans.
For the second consecutive year, the tabletop exercise... Read More »
Novavax, Inc. demonstrated a strong showing of its COVID-19 vaccine last week, posting an 89.3 percent efficacy in a United Kingdom-based phase three trial, conducted in partnership with the UK government’s Vaccines Taskforce.
Notably, this vaccine was also pitted against variants of the... Read More »
Even with the rollout of mass vaccination worldwide, COVID-19’s spread is nowhere near an immediate end.
So, it might seem perplexing when biosecurity researchers appear optimistic about a future without pandemics.
That reality is exactly what a new report has outlined. Released this week... Read More »
The results of the phase three ENSEMBLE clinical trial have shown that Johnson & Johnson’s single-shot Janssen COVID-19 vaccine candidate is 66 percent effective overall at preventing moderate to severe COVID-19 cases 28 days after vaccination.
The study also showed that the vaccine... Read More »
Combatting Antibiotic-Resistant Bacteria (CARB-X) awarded $5.3 million to Lumen Bioscience to develop a new immunotherapy to prevent diarrheal diseases caused by two specific pathogens -- Campylobacter jejuni and enterotoxigenic E. coli.
Diarrheal diseases are intestinal infections caused by... Read More »
The RTS,S/AS01E malaria vaccine is the focus of a new product transfer agreement between GSK, PATH, and Bharat Biotech (BBIL), which will see manufacturing, supply, and rights split between the three entities.
Under the arrangement, manufacturing of the RTS,S antigen and licensing rights to the... Read More »
A new agreement between Sanofi and BioNTech grants the latter access to Sanofi’s infrastructure to aid manufacturing of the COVID-19 vaccine BioNTech has co-developed with Pfizer, granting them the ability to make more than 125 million doses for Europe from summer on.
“Although vaccination... Read More »
The Biden administration’s plan to tackle COVID-19 includes delivering at least 100 million vaccines in 100 days to the American people. As of this week it was also announced that the federal government purchased 200 million additional doses from Moderna and Pfizer-BioNTech, enough to vaccinate... Read More »
Specialty vaccine company Valneva and Instituto Butantan signed an agreement to develop Valneva’s single-shot chikungunya vaccine, VLA1553, in low- and middle-income countries (LMICs).
As part of the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan,... Read More »
In new data released by Eli Lilly and Company, a cocktail of neutralizing antibodies bamlanivimab and etesevimab reduced COVID-19 related hospitalizations and deaths by 70 percent among more than 1,000 high-risk patients.
According to the report, which was based on the BLAZE-1 phase three... Read More »
Boeing and Sikorsky personnel have detailed its advanced helicopter, DEFIANT X, which will be entered into the Army’s Future Long Range Assault Aircraft (FLRAA) competition.
The companies indicated DEFIANT X would be the fastest, most maneuverable, and most survivable assault helicopter in... Read More »
Although well-tolerated, Merck’s two COVID-19 vaccine candidates -- V590 and V591 -- have been discontinued due to immune responses well below those provided by natural infection or other vaccines.
“We are grateful to our collaborators who worked with us on these vaccine candidates and to... Read More »
The development and deployment of an effective vaccine for COVID-19 could be the turning point in the fight against the deadly pandemic, and companies involved in the process must make specific business and public health considerations simultaneously to help ensure a successful outcome, experts... Read More »
Emergent BioSolutions and Humanigen have signed a contract development and manufacturing (CDMO) services agreement to accelerate the manufacturing of the drug lenzilumab.
Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent... Read More »
In a manuscript posted to a preprint server, Moderna Inc. addressed Monday the results of in vitro neutralization studies of sera from people vaccinated against emerging strains of SARS-CoV-2, which produced lesser, though still protective, results.
Specifically, the variants being fretted over... Read More »
The Nuclear Threat Initiative applauded the Biden Administration for extending the New Strategic Arms Reduction Treaty (New START) with Russia for an additional five years.
The New START agreement was reached in 2011 with Russia to reduce nuclear arms in both countries. The 10-year agreement was... Read More »
COVAX announced last week that a new purchase agreement with Pfizer-BioNTech will secure up to 40 million doses of COVID-19 vaccine for rollout, offering the potential to deliver at least 2 billion doses of vaccines, equitably, by year’s end.
“Today marks another milestone for COVAX:... Read More »
The Oklahoma Pandemic Center for Innovation and Excellence (OPCIE) officially opened in Stillwater, Okla., this week, presenting a new lab, genetic biorepository, and science lab to address public health concerns.
The facility is meant to serve as a frontline of defense against future... Read More »
The U.S. Department of Transportation’s Maritime Administration (MARAD) gave the go-ahead to build two additional National Security Multi-Mission Vessels (NSMV).
These vessels will replace aging training vessels at Maine Maritime Academy in Castine, Me., and Texas A&M Maritime Academy in... Read More »
Chalmers University of Technology researchers have determined that significant genetic transfer between bacteria in our ecosystems and humans may be linked to pathogenic bacteria in humans developing resistance to antibiotics.
"In recent years, we've seen that resistance genes spread to human... Read More »
ConserV Bioscience Limited (CBL) and the Lawrence Livermore National Laboratory (LLNL) agreed to collaborate this week in creating a universal coronavirus vaccine capable of protecting against coronavirus pathogens of human and animal origin, as well as new mutations, researchers said.
CBL, a... Read More »
The World Health Organization (WHO) hosted a virtual forum last week to identify knowledge gaps and set research priorities for vaccines against COVID-19.
At the forum – attended by more than 2,800 scientists from 130 countries – the participants discussed the safety and efficacy of existing... Read More »
With £2.5 million in funding from UK Research and Innovation, an arm of the government, the G2P-UK National Virology Consortium has been founded to study the threats posed by new SARS-CoV-2 variants increasingly cropping up across the world.
The effects of these mutations have yet to be fully... Read More »
The Departments of Defense (DoD) and Health and Human Services (HHS) awarded $69.3 million to CONTINUUS Pharmaceuticals Inc. last week to support the development of domestic production capability for critical medicines using integrated continuous manufacturing (ICM) technology.
ICM is a... Read More »
Northrop Grumman Corporation's Integrated Air and Missile Defense Battle Command System (IBCS), which the company developed with the Army, would proceed with low rate initial production (LRIP).
The action stems from a successful Milestone C decision for the program, which the Department of... Read More »
The Rockefeller Foundation seeks to boost vaccination efforts in the United States with a $30 million new advance market commitment (AMC) with Thermo Fisher Scientific to procure and stock COVID-19 tests.
The investment will provide guaranteed demand to test manufacturers. In return, the stock... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) and U.S. Department of Defense (DoD) will be able to purchase more than 2 million additional COVID-19 antibody treatments due to modifications to an existing agreement with Eli Lilly and Company.
The therapeutic in question,... Read More »
As DiaSorin Molecular LLC works to create a combination diagnostic for differentiating between influenza A/B and COVID-19, it will receive funding, technical assistance, and the expertise of the Biomedical Advanced Research and Development Authority (BARDA).
The announcement, made this week,... Read More »
